CD34抗原在急性双表型白血病的临床研究  

Clinical Study on Role of CD34 in Patients with Biphenotypic Acute Leukemia

作　　者：鲁广建[1] 宋志善[2] 张群妹[1] 李平法[2] 

机构地区：[1]新乡医学院第一附属医院检验科,河南卫辉453100 [2]新乡医学院医学检验系,河南新乡453003

出　　处：《中国实验血液学杂志》2014年第5期1226-1229,共4页Journal of Experimental Hematology

摘　　要：本研究旨在探讨白细胞CD34抗原在急性双表型白血病(biphenotypic acute leukemia,BAL)的表达情况,以明确其与BAL预后的关系。应用流式细胞仪检测白血病相关抗原,所用单克隆抗体B淋巴细胞系列为CD10,CD19和CD34;T淋巴细胞系列为CD2,CD3和CD5;髓系为MPO,CD13和CD33,最终对结果进行分析。结果表明:216例急性白血病患者中9例(4.2%)被诊断为急性双表型白血病,其中髓系和B淋巴细胞系共同表达6例(66.7%),髓系和T淋巴细胞系共同表达3例(33.3%)。4例CD34表达阳性(44.4%)与急性髓系白血病和急性淋巴细胞白血病相比,双表型急性白血病患者表现出显着较高的CD34抗原阳性表达率(P<0.05)。结论:与急性髓细胞性白血病或急性淋巴细胞白血病相比,急性双表型白血病患者的预后较差,CD34阳性表达可能与急性双表型白血病的治疗效果呈负相关。This study was aimed to explore the expression of CD34 in patients with biphenotypic acute leukemia （BAL） and its relation with the prognosis of BAL.The flow cytometry was used to detect leukemia-associated antigen.The used monoclonal antibodys （McAb） included CD10,CD19 and CD34 for B lymphocyte lineage,CD2,CD3 and CD5 for T lymohocyte lineage,MPO,CD13 and CD33 for myeloid lineage.The finally results were respectively analyzed.The results indicated that 9 out of 216 cases of leukemia was diagnosed as BAL （4.2%）.Among 9 cases of BAL,6 cases showed the common expression of myeloid and T lymohocyte lineages （66.7%）,3 cases showed the common expression of myeloid and B lymohocyte lineages （33.3%）.4 cases of BAL displayed CD34 positive expression （44.4%）.As compared with acute myelogenous leukemia （AML） and acute lymphoblastic leukemia （ALL）,the BAL patients showed higher CD34 positive expression （P 〈 0.05）.It is concluded that the BAL patients show a poor prognosis,as compared with AML or ALL patients.The therapeutic effect of BAL may negatively correlate with the CD34 positive expression.

关 键 词：急性双表型白血病 免疫分型 CD34 

分 类 号：R733.71[医药卫生—肿瘤]